BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma

被引：6

作者：

Sakellari, Ioanna ^{[1
]}

Gavriilaki, Eleni ^{[1
]}

Bouziana, Stella ^{[1
]}

Constantinou, Varnavas ^{[1
]}

Mallouri, Despina ^{[1
]}

Vardi, Anna ^{[1
]}

Marvaki, Anastasia ^{[1
]}

Batsis, Ioannis ^{[1
]}

Sotiropoulos, Damianos ^{[1
]}

Anagnostopoulos, Achilles ^{[1
]}

机构：

[1] George Papanicolaou Hosp, Dept Hematol, BMT Unit, Thessaloniki, Greece

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 06期

关键词：

CHEMOTHERAPY; THERAPY;

D O I：

10.1038/s41409-018-0395-y

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：921 / 923

页数：3

共 7 条

[1] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [J].

Armand, Philippe ;

Engert, Andreas ;

Younes, Anas ;

Fanale, Michelle ;

Santoro, Armando ;

Zinzani, Pier Luigi ;

Timmerman, John M. ;

Collins, Graham P. ;

Ramchandren, Radhakrishnan ;

Cohen, Jonathon B. ;

De Boer, Jan Paul ;

Kuruvilla, John ;

Savage, Kerry J. ;

Trneny, Marek ;

Shipp, Margaret A. ;

Kato, Kazunobu ;

Sumbul, Anne ;

Farsaci, Benedetto ;

Ansell, Stephen M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (14) :1428-+

[2] Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation [J].

Kuittinen, T. ;

Jantunen, E. ;

Vanninen, E. ;

Mussalo, H. ;

Vuolteenaho, O. ;

Ala-Kopsala, M. ;

Nousiainen, T. ;

Hartikainen, J. .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (02) :120-127

[3] Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation [J].

Kuittinen, T ;

Husso-Saastamoinen, M ;

Sipola, P ;

Vuolteenaho, O ;

Ala-Kopsala, M ;

Nousiainen, T ;

Jantunen, E ;

Hartikainen, J .

BONE MARROW TRANSPLANTATION, 2005, 36 (12) :1077-1082

[4] Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Moskowitz, Craig H. ;

Nademanee, Auayporn ;

Masszi, Tamas ;

Agura, Edward ;

Holowiecki, Jerzy ;

Abidi, Muneer H. ;

Chen, Andy I. ;

Stiff, Patrick ;

Gianni, Alessandro M. ;

Carella, Angelo ;

Osmanov, Dzhelil ;

Bachanova, Veronika ;

Sweetenham, John ;

Sureda, Anna ;

Huebner, Dirk ;

Sievers, Eric L. ;

Chi, Andy ;

Larsen, Emily K. ;

Hunder, Naomi N. ;

Walewski, Jan .

LANCET, 2015, 385 (9980) :1853-1862

[5]

Robinson SP, 2018, BONE MARROW TRANSPLA

[6] Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas [J].

Sakellari, Ioanna ;

Mallouri, Despoina ;

Batsis, Ioannis ;

Apostolou, Chrysa ;

Konstantinou, Varnavas ;

Abela, Eleni-Maria ;

Douka, Vasiliki ;

Marvaki, Anastasia ;

Karypidis, Kyriakos ;

Iskas, Michalis ;

Baliakas, Panayiotis ;

Kaloyannidis, Panayotis ;

Yannaki, Evangelia ;

Sotiropoulos, Damianos ;

Kouvatseas, Giorgos ;

Smias, Christos ;

Anagnostopoulos, Achilles .

LEUKEMIA & LYMPHOMA, 2015, 56 (11) :3071-3081

[7] Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity [J].

Shi, Youwu ;

Liu, Peng ;

Zhou, Shengyu ;

Yang, Jianliang ;

Han, Xiaohong ;

He, Xiaohui ;

Zhang, Changgong ;

Gui, Lin ;

Qin, Yan ;

Yang, Sheng ;

Zhao, Liya ;

Yao, Jiarui ;

Jia, Bo ;

Zhang, Shuxiang ;

Sun, Yan ;

Shi, Yuankai .

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) :E423-E429

← 1 →